Phase II Trial of CDX-3379 and Cetuximab in Recurrent/Metastatic, HPV-Negative, Cetuximab-Resistant Head and Neck Cancer

SIMPLE SUMMARY: This phase II, Simon 2-stage, multicenter study evaluated the efficacy of the combination of CDX-3379 and cetuximab, monoclonal antibodies against ErbB3 and EGFR, respectively, in patients with recurrent/metastatic, HPV-negative, cetuximab-resistant head and neck cancer. The primary...

Descripción completa

Detalles Bibliográficos
Autores principales: Bauman, Julie E., Julian, Ricklie, Saba, Nabil F., Wise-Draper, Trisha M., Adkins, Douglas R., O’Brien, Paul, Fidler, Mary Jo, Gibson, Michael K., Duvvuri, Umamaheswar, Heath-Chiozzi, Margo, Alvarado, Diego, Gedrich, Richard, Golden, Philip, Cohen, Roger B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9139981/
https://www.ncbi.nlm.nih.gov/pubmed/35625959
http://dx.doi.org/10.3390/cancers14102355

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9139981/
https://www.ncbi.nlm.nih.gov/pubmed/35625959
http://dx.doi.org/10.3390/cancers14102355

Ejemplares similares